HK Stock MarketDetailed Quotes
01672 ASCLETIS-B
- 2.080
- -0.010-0.48%
Not Open Dec 12 16:08 CST
2.02BMarket Cap-7.15P/E (TTM)
2.110High1.970Low2.46MVolume2.090Open2.090Pre Close5.07MTurnover0.25%Turnover RatioLossP/E (Static)972.83MShares2.12052wk High0.85P/B2.02BFloat Cap0.76052wk Low--Dividend TTM972.83MShs Float14.900Historical High--Dividend LFY6.70%Amplitude0.760Historical Low2.059Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
About ASCLETIS-B Company
Curie was founded in 2013 and listed on the Hong Kong Stock Exchange in 2018 (1672.HK). Geli is committed to the development and commercialization of innovative drugs in the fields of viral diseases, non-alcoholic steatohepatitis, and tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors) to meet the clinical needs of patients at home and abroad. Ganlai Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Goli Pharmaceuticals Group and focuses on the development and commercialization of innovative drugs in the field of NASH disease.
Company Profile
Symbol01672
Company NameASCLETIS-B
ISINKYG0520K1094
Listing DateAug 1, 2018
Issue Price14.00
Shares Offered224.14M share(s)
FoundedFeb 25, 2014
Registered AddressCayman Islands
Chairmanjinzi wu
Secretaryminghui zhong
Audit InstitutionKPMG
Company CategoryOther
Registered Office190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees219
MarketHong Kong motherboard
Phone(86)57185389730
Emailir@ascletis.com
Websitehttp://www.ascletis.com
Business Goli Pharmaceutical Co., Ltd. is a Chinese investment holding company mainly engaged in R&D, production, marketing and sales of pharmaceutical products. The company mainly focuses on viral diseases, non-alcoholic steatohepatitis, and oncology. The viral disease product pipeline includes ritonavir, lavidavir hydrochloride, danolavir sodium, etc. Non-alcoholic steatohepatitis product lines include ASC40, ASC41, ASC42, etc. The tumor product pipeline includes ASC60, ASC61, etc.
Company Executives
- Name
- Position
- Salary
- jinzi wu
- Chairman of the Board, CEO, Executive Director, Chairman of the Nomination Committee, Authorized Representative
- --
- jingdao he
- VP, Executive Director, Remuneration Committee Members, Authorized Representative
- --
- yizhen wei
- Independent Non-Executive Director, Remuneration Committee Members, Audit Committee Members, Nomination Committee Members
- --
- jiong gu
- Independent Non-Executive Director, Chairman of the Audit Committee
- --
- lin hua
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
- --
- John P.GARGIULO
- Chief Scientist
- --
- yuemei yan
- VP
- --
- minghui zhong
- Company Secretary
- --
Heat List
HK
Overall
Symbol
Price
% Chg
No Data
